$LAWIL

Light & Wonder, Inc. (LAWIL): Results of Operations and Financial Condition

Light & Wonder, Inc. (LAWIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lnw06302026erandtables.htm EX-99.1 Document Light & Wonder, Inc. Reports Second Quarter 2026 Results Light & Wonder Reports Solid Second Quarter 2026 Results and Reiterates Full-Year 2026 Financial Outlook (1) Financial Highlights • Net income increased 26% to $120 mill

Original reporting
Published Aug 4, 2026, 9:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$LAWIL
Bullish
medium confidence
Mentioned
$LAWIL
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LAWILBullishMed
01

Why it matters

Traders can update expectations for earnings quality (recurring revenue mix), cash generation, and capital returns, while monitoring whether the reiterated full-year outlook aligns with the company’s de-leveraging plan.

02

Market read

A primary earnings and capital allocation disclosure with multiple hard datapoints (income, AEBITDA, cash flow, buyback pace) and a specific leverage target, which can drive positioning into subsequent quarters.

03

What to watch

The leverage target (below 3.0x by 1H 2027) implies future capital allocation trade-offs; aggressive buybacks could become less supportive if deleveraging requires faster balance-sheet improvement.

Relevance 7/10Novelty 8/10Timing: after-hours filing on Aug 4, 2026, for Q2 ended June 30, 2026

Background

This is Light & Wonder’s SEC Form 8-K attaching results for the second quarter ended June 30, 2026, including non-GAAP metrics and capital allocation updates.

Company-level read

Ticker impact

$LAWILBullishMedium confidence
Context

Light & Wonder reported Q2 2026 results with net income up 26% to $120M, consolidated AEBITDA up 9% to $383M, and reiterated full-year 2026 outlook.

Expected impact

Likely positive near-term bias, with follow-through dependent on whether the reiterated full-year outlook is viewed as credible versus leverage reduction.

Evidence & confidence

The filing provides multiple concrete datapoints (earnings, AEBITDA, operating cash flow, adjusted free cash flow, and buyback pace) and a specific balance-sheet target (net debt leverage below 3.0x by 1H 2027), which traders can map to valuation and risk.

Market effects

Supports the broader gaming and iGaming software/services tape by reinforcing demand and margin resilience tied to content and recurring revenue mix.

Highlights North America momentum (premium installed base growth and iGaming double-digit growth) while noting UK tax headwinds.

Reiterated full-year outlook and cash-flow strength can influence cross-border sentiment toward diversified gaming operators with recurring revenue.

Counterpoint

Gaming machine sales revenue declined 4% due to fewer new openings and expansions, which could cap upside if the unit shipment slowdown persists.

Key entities

  • Light & Wonder, Inc.

    Reported Q2 2026 results, margin expansion, strong operating cash flow, accelerated share repurchases, and a net debt leverage target below 3.0x by 1H 2027.

  • Matt Wilson

    CEO quote emphasizing content-centric operating model, gaming momentum, and continued investment while progressing toward 2026 and 2028 targets.

  • Oliver Chow

    CFO quote highlighting margin-driven cash generation, accelerated buybacks, and focus on rapid de-leveraging.

Related articles

$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.

$GXOMed

GXO Logistics Q2 Earnings Call Highlights

GXO Logistics reported Q2 results and said it secured over $1 billion in expected incremental new-business revenue for 2026 and about $353 million for 2027. Management cited a $2.7 billion sales pipeline after quarter end. Operating cash flow was $76 million, free cash flow positive $12 million, cash $769 million, and net leverage 2.6x. GXO plans to target EBIT margins above 6% and deploy AI across ~50 sites in 2026.

$GRNDMed

Grindr Q2 Earnings Call Highlights

Grindr (NYSE:GRND) said free users remain central to its strategy, while AI tools are boosting engineering productivity. Management estimated engineering output rose about 2.5x from July 2025 to April 2026 with similar headcount, supporting a 39% to 42% adjusted EBITDA margin outlook. EDGE AI premium tier rollout is planned for later in fall; operating expenses ex cost of revenue were $71M vs $53M.

$HAEMedAI 8/10

Haemonetics Q1 Earnings Call Highlights

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.